(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot' - 2How on earth did 'Shark Tank' star Kevin O'Leary end up in 'Marty Supreme'? I'll let him explain.
- 3Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- 4Figure out How to Keep up with Oral Wellbeing During Pregnancy
- 5The Most Important Crossroads in Olympic History
- The Best Music Collections of the 10 years
- Witness the elegance of the cosmic butterfly in a remarkable telescope photo
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- Civil rights leader Jesse Jackson hospitalized, family requests prayers
- 6 Fun Urban areas For Seniors To Travel
- A definitive Manual for Well known Fragrances
- Cyber Monday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- Careful Living: Embracing the Current Second
